Navigation Links
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Date:11/2/2007

the standard of care. The study found:

-- Up to 81 percent of those patients treated with R1626 1500 mg (twice-

daily) + PEGASYS + COPEGUS had an undetectable HCV viral load by week

four (mean reduction of 5.2 log10 IU/mL)

-- ALT, a liver enzyme, normalized in approximately 50 percent of patients

in R1626 treatment groups

-- Most reported adverse events were mild to moderate. Dose dependent,

reversible grade four neutropenia was observed in the R1626 arms (36

percent in patients receiving R1626 1500 mg + PEGASYS + COPEGUS), and

was the main reason for dose reduction and discontinuation

Lack of Resistance

According to a second presentation at the conference, resistance to R1626 was not identified following intensive testing for either two weeks of treatment with R1626 as monotherapy, or in patients treated with R1626 for four weeks in combination with the standard of care. These findings suggest that there is a high barrier to the development of resistance to R1626 in vivo.

Start of Phase IIb Trial

R1626 is being progressed into Phase IIb study, called POLI 1, to further investigate the new treatment regimens of R1626, in combination with standard or lower dose of PEGASYS and standard dose of COPEGUS. This Phase IIb trial is now open and enrolling patients in eight countries, including the United States. More information about R1626 and the clinical studies can be found on http://www.roche-trials.com.

"As a clinician, I am excited by the high rates of viral negativity that were observed after four weeks of treatment with R1626 in combination with the standard of care. The design of the Phase IIb study should enable us to find the doses of R1626, PEGASYS and COPEGUS that achieve the appropriate balance between safety and efficacy," said Dr. David Nelson, Director of Hepatology and Liver Transplantation at the
'/>"/>

SOURCE Roche
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
2. An Investigational Study Released at ADA Showed that Initial Combination Therapy with Januvia (sitagliptin) and Metformin Led to Improvement in Markers of Beta Cell Function in Patients with Type 2 Diabetes
3. Late Breaking Data Released at ADA Showed that the Investigational Use of Januvia and Metformin as Initial Combination Therapy Provided Significant Glucose Lowering Efficacy over 54 Weeks in Patients with Type 2 Diabetes
4. Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
5. Mercks Investigational Migraine Treatment MK-0974 Significantly Improved Migraine Pain on Several Efficacy Measures in a Phase II Study
6. Data Demonstrated Metastatic Melanoma Response to Investigational Immunotherapy Ipilimumab
7. Investigational Drug Cediranib (AZD2171) Shows Promise in Patients With Recurrent Glioblastoma (GBM)
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
10. Investigational Cancer Drug Pertuzumab Shows Promising Results in Advanced Breast Cancer When Combined with Herceptin
11. Shire Announces Positive Results of Studies With Guanfacine Extended Release, An Investigational Nonstimulant Medication Filed for the Treatment of ADHD in Children and Adolescents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , October 22, 2014 A ... Gloves Market (Product type, Form, End user, Application and ... Insights, Analysis, Research, Report, Opportunities, Segmentation and Forecast, 2013 ... gloves market. Based on key trends tracked, it is ... at $7.9 billion by 2020, registering a CAGR of ...
(Date:10/22/2014)... LOUIS , Oct. 21, 2014  Early ... often subtle or unnoticed, but new technology, coupled ... outcomes and leading to earlier detection of eye ... affects 29 million Americans. If left untreated, these ... even blindness. Recently, optometric researchers ...
(Date:10/22/2014)... NEW YORK , Oct. 22, 2014 ... an August 2014 report by Global Research & Data ... 6.2% per year from 2014 through 2018, as demand ... United States is the world,s largest market ... market with advanced thermometers is Sanomedics International Holdings, Inc. ...
Breaking Medicine Technology:Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3Sanomedics International Holdings Analyst Report: Taking Some Heat by BrokerBank Securities, Inc. 2
(Date:10/22/2014)... 22, 2014 Lintelus, Inc., an event ... President of Sales, will be speaking on the subject ... Expo on October 28, at the Holiday Inn in ... booth as well as a Tech Demo at 12:45pm, ... create a more engaging event experience. , The Annual ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 (HealthDay ... be showing a genetic propensity for obesity as toddlers, a ... linked to increased body fat, but the same genes in ... researchers said. At 1 year, kids with these genes ... however, these genes were linked to excessive weight gain, the ...
(Date:10/22/2014)... Tara Haelle HealthDay Reporter ... drinking among young adult men may lead to increased blood ... didn,t cause a similar rise in blood pressure for young ... fact, when young adult women drank lightly or moderately, their ... study found. "This finding parallels studies in older adult ...
(Date:10/22/2014)... HealthDay Reporter , MONDAY, Oct. 20, 2014 (HealthDay ... for health workers treating Ebola patients, now requiring full body ... at all times. The U.S. Centers for Disease Control ... Dallas nurses contracted Ebola while caring for the first ... Duncan. Nina Pham is currently being treated for her infection ...
(Date:10/20/2014)... Orlando, Florida (PRWEB) October 20, 2014 ... fired-up former Gov. Charlie Crist made a brief fundraising ...  in Orlando on Thursday. , Fresh from a debate ... refused to take the stage for the first seven ... podium, the former governor described the incident in one ...
Breaking Medicine News(10 mins):Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 2Health News:Binge Drinking May Boost Blood Pressure in Young Men 3Health News:Binge Drinking May Boost Blood Pressure in Young Men 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 2Health News:At Crist Fundraiser, Dan Newlin Says, "No More Robert Germans," Will Seek Changes to Florida Missing Persons Law 3
... Union asks board member to seek restatement of Beth ... Staples director Martin Trust,should apply the same Sarbanes-Oxley standards ... role on the board of Beth Israel Deaconess,Medical Center ... East. Trust is the CEO of Samtex and a ...
... Advisory Board Company,(Nasdaq: ABCO ) announced today ... Michael T. Kirshbaum, Chief Financial Officer and Robert,Musslewhite, ... upcoming investor conferences., Mr. Williams will present ... at,the UBS 18th Annual Global Healthcare Services Conference, ...
... in Long-Term Care: A Board of Directors Dashboard, ... Office of Inspector General (OIG) for the Department of ... Association (HCCA),present the challenges and opportunities for the boards ... of Care Dashboard." A,Quality of Care Dashboard is a ...
... Fla., Feb. 6 Mangrove Employer Services, a,leading ... Payroll, Benefits Administration and Self Service solutions,announces the ... Mangrove Employer Services teamed up with an ... in electronic benefits,payment services, in 2007 to provide ...
... NAPA, Calif., Feb. 6 Senetek PLC (OTC,Bulletin ... the development,of technologies that target the science of ... on Pyratine-6(TM) at the 66th Annual Meeting,of the ... In his presentation to the Academy, Dr. ...
... after , , WEDNESDAY, Feb. 6 (HealthDay News) -- An advanced ... harbingers of Alzheimer,s disease, can develop in just 24 hours. ... Hyman, leader of the group reporting the finding in the ... develop, damage is evident in nearby nerve cells almost immediately, ...
Cached Medicine News:Health News:Staples Board Member Should Use Sarbanes-Oxley Disclosure Rules in Non-Profit Role, Asserts 1199 SEIU 2Health News:The Advisory Board Company to Present at Upcoming Conferences 2Health News:OIG and HCCA Issue Government-Industry Roundtable Report 2Health News:Mangrove Announces Health Savings Account (HSA) and Health Reimbursement Account (HRA) Product Launches 2Health News:Dr. Neil Sadick Presents on Pyratine-6(TM) at the Annual Meeting of the American Academy of Dermatology 2Health News:Alzheimer's Plaques Can Form in One Day 2
... Amvex offers a complete line of flowmeters, available ... are all available in a variety of calibrations to ... dials specific to the gas in use, the Amvex ... colors replace the U with I. For Power Take-Off ...
0-3.5 LPM Oxygen Flowmeter with Chemetronmale inlet...
0-15 LPM Oxygen Flowmeter with Chemetron male inlet...
(1/4-15 LPM). 50 psi back inlet, wall mounted, 1/8" NPT female....
Medicine Products: